Results 191 to 200 of about 8,763,296 (354)

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Repeated observation of breast tumor subtypes in independent gene expression data sets

Proceedings of the National Academy of Sciences of the United States of America, 2003
T. Sørlie, R. Tibshirani, Joel Parker, T. Hastie, J. Marron, A. Nobel, Shibing Deng, H. Johnsen, Robert Pesich, S. Geisler, J. Demeter, C. Perou, P. Lønning, P. Brown, A. Børresen-Dale, D. Botstein   +15 more
semanticscholar   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

The Liver Tumor Segmentation Benchmark (LiTS) [PDF]

Medical Image Anal., 2019
Patrick Bilic, P. Christ, Eugene Vorontsov, G. Chlebus, Hao Chen, Q. Dou, Chi-Wing Fu, Xiao Han, P. Heng, J. Hesser, S. Kadoury, Tomasz K. Konopczynski, Miao Le, Chunming Li, X. Li, Jana Lipková, J. Lowengrub, H. Meine, J. Moltz, C. Pal, M. Piraud, Xiaojuan Qi, Jin Qi, M. Rempfler, Karsten Roth, A. Schenk, A. Sekuboyina, Ping Zhou, Christian Hülsemeyer, M. Beetz, Florian Ettlinger, Felix Grün, Georgios Kaissis, F. Lohöfer, R. Braren, J. Holch, Felix O. Hofmann, W. Sommer, V. Heinemann, C. Jacobs, G. Mamani, B. Ginneken, G. Chartrand, A. Tang, M. Drozdzal, Avi Ben-Cohen, E. Klang, M. Amitai, E. Konen, H. Greenspan, Johan Moreau, A. Hostettler, L. Soler, R. Vivanti, Adi Szeskin, N. Lev-Cohain, J. Sosna, Leo Joskowicz, Bjoern H Menze, ZENGMING SHEN   +59 more
semanticscholar   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Enhancing anti-tumour immunity through modulating dendritic cell activation by combination therapy with a novel TLR2 agonist and PD-L1 Blockade. [PDF]

J Exp Clin Cancer Res
Wang C, Ai Z, Wang Y, Luo M, Wu T, Wang D, Liu X, Lv J, Guo X, Wang Z, Sun Q, Liao X, Wu L.   +12 more
europepmc   +1 more source

Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems [PDF]

, 2012
Yuqing Ma, Qiao‐Xin Li, Wenli Cui, Na Miao, Xia Liu, Wei Zhang, Chen Zhang, Jian Wang   +7 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Artificial Intelligence computed tomography models for the discrimination of Wilms versus non-Wilms tumors: systematic review and meta-analysis. [PDF]

J Bras Nefrol
Feitosa Filho HN, Lima RV, Furtado JFCU, Ohannesian VA, Eulálio EC, Ribeiro PVC, Paiva LMA, Feitosa ID, Silva Júnior GBD.   +8 more
europepmc   +1 more source

Assessment of Tumoricidal Efficacy and Response to Treatment with¹⁸F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor [PDF]

, 2011
Eleni Liapi, Jean-François H. Geschwind, Mustafa Vali, Afsheen Khwaja, Veronica Prieto-Ventura, Manon Buijs, Josephina A. Vossen, Shanmugasudaram Ganapathy, Richard L. Wahl   +8 more
openalex   +1 more source